COMPEL Data Show Osimertinib Plus Chemo Beats Chemo Alone for EGFRm NSCLC Following Progression
Osimertinib is a targeted treatment often used as the first option for people with non-small cell lung cancer (NSCLC) that has EGFR mutations. When the cancer stops responding, the usual next step has been chemotherapy with platinum drugs. But results from the global COMPEL trial suggest that staying on osimertinib and adding chemotherapy (platinum with pemetrexed) works better than chemotherapy alone for patients whose cancer grows after first-line osimertinib, as long as it hasn’t spread inside the brain.
“Cancer progression on osimertinib doesn’t always happen the same way,” explained Dr. Giulia Pasello, Associate Professor of Oncology at the University of Padova in Italy. “In some cases, especially in the brain and central nervous system, cancer cells may still respond to osimertinib. That means the drug could continue to protect the brain even after the cancer has started to grow elsewhere.”
Read the full article here.